Sanofi/Genzyme MS Drug Lemtrada Scores High Against Rebif

Genzyme, a Sanofi company, set the bar high for its multiple sclerosis contender by stacking it up against Roche’s interferon beta-1a in Phase III trials and got the results it was looking for, with a filing set for this quarter.

More from Clinical Trials

More from R&D